Phytopharm's Cogane fails Phase II PD trial
Phytopharm plc (LSE:PYM) said once-daily doses of oral Cogane for up to 28 weeks missed the primary endpoint and all secondary endpoints in the 400-patient Phase II CONFIDENT-PD trial to treat early stage Parkinson's disease (PD). The primary endpoint was an improvement in the combined activities of daily living and motor scores from baseline to the end of treatment vs. placebo. Phytopharm said it plans to further analyze the data in the coming weeks to determine whether or not to continue development of the synthetic, orally-active neurotrophic factor modulator, as well as the company's Myogane, a non-peptide neurotrophic factor modulator in preclinical development for glaucoma. Last year, the company said that Myogane produced inconclusive results in a preclinical glaucoma model. ...